Clinical features and treatment outcomes of PD-1 inhibitor therapy in elderly patients ( ≥ 65 years) with advanced esophageal squamous cell carcinoma: a real-world study
ConclusionThe study demonstrated that individuals older than 65 years with locally advanced or metastatic ESCC have a survival benefit from the first-line treatment of PD-1 inhibitors combined therapy, with a manageable safety profile.
Source: Clinical and Translational Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer & Oncology | Carcinoma | Chemotherapy | Esophagus Cancer | Skin Cancer | Squamous Cell Carcinoma | Study